For the Inventor, By the Inventor

Enter assignee name

Medicago Inc.

Calculating rank

USPTO Granted Patents = 31

% Expired Patents = 12.9

CIPO Patents = 45

EPO Patents = 31

Trademarks = 16

Forward Citations = 449

Loading Chart...

Loading Chart...

40 inventors (with patents filed for the assignee):

Marc-Andre D'Aoust (23 out of 35 patents)

Louis-Philippe Vezina (19 out of 23 patents)

Manon Couture (16 out of 21 patents)

4. Pierre-Olivier Lavoie (13 out of 21 patents)

5. Michele Dargis (7 out of 7 patents)

6. Nathalie Landry (7 out of 9 patents)

7. Frederic Ors (4 out of 7 patents)

8. Sonia Trepanier (4 out of 4 patents)

9. Dany Paquet (3 out of 3 patents)

10. Marc-André D'Aoust (3 out of 3 patents)

11. Dominique Michaud (2 out of 3 patents)

12. Frank Sainsbury (2 out of 2 patents)

13. Daniel F Voytas (2 out of 29 patents)

14. Thomas Stoddard (2 out of 4 patents)

15. Luc Mathis (2 out of 6 patents)

Core Competencies:

CPMV Enhancer Elements

Plant-Derived VLPs

Nicotiana Plants

Influenza Virus-Like Particles

Modified Norovirus Proteins

Jasmonic Acid Pathway

Transgenic Plants

Protein Yield

Fusion Proteins

Chimeric VLPs

Sialic Acid Synthesis

Regulating Gene Expression

31 patents: Sort by Forward Citations

1. 11884929 - CPMV enhancer elements (2024-01-30),

2. 11833200 - Method of preparing plant-derived proteins (2023-12-05),

3. 11826419 - Method of preparing plant-derived VLPs (2023-11-28),

4. 11759512 - Modified norovirus VP1 proteins and VLPs comprising modified norovirus VP1 proteins (2023-09-19),

5. 11608361 - Norovirus fusion proteins and VLPS comprising norovirus fusion proteins (2023-03-21),

6. 11602558 - Modified norovirus VP1 proteins and VLPS comprising modified norovirus VP1 proteins (2023-03-14),

7. 11576317 - Mutantplant or cell with reduced XylT and FucT (2023-02-14),

8. 11555198 - Method for making nicotiana plants with mutations in XylT and FucT alleles using rare-cutting endonucleases (2023-01-17),

9. 11441150 - CPMV enhancer elements (2022-09-13),

10. 11434497 - Recombinant influenza virus-like particles (VLPS) produced in transgenic plants (2022-09-06),

11. 11390878 - Increasing protein yield in plants (2022-07-19),

12. 11155581 - Increasing virus-like particle yield in plants (2021-10-26),

13. 11085049 - Influenza virus-like particle production in plants (2021-08-10),

14. 10907168 - Jasmonic acid pathway activator (2021-02-02),

15. 10590173 - Picornavirus-like particle production in plants (2020-03-17),

Company Overview

Medicago Inc. is a biotechnology company based in Quebec, Canada, specializing in the development of innovative plant-based vaccines and therapeutics. The company leverages its proprietary technology platform to produce recombinant proteins, which are essential for creating vaccines against infectious diseases. Medicago's research focuses on harnessing the potential of plants to generate safe and effective medical solutions, contributing to global health initiatives and advancing the field of immunization.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Nov 10 2026

31 Patents

#12 in Quebec

#444 in Canada

#21,334 in the World

Medicago Inc.

Forward Citations = 449

40 inventors:

Marc-Andre D'Aoust (23 out of 35 patents)

Louis-Philippe Vezina (19 out of 23 patents)

Manon Couture (16 out of 21 patents)

4. Pierre-Olivier Lavoie (13 out of 21 patents)

5. Michele Dargis (7 out of 7 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Medicago Inc.. Retrieved from https://idiyas.com/company/medicago

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…